Advertisement


Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma. (Abstract 80)



Related Videos

Skin Cancer

Marie-Andrée Forget, PhD, on Metastatic Melanoma: Update From MD Anderson

Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumo...

Lung Cancer

Limo Chen, PhD, on Lung Cancer and CD38: Resistance to Immunotherapy

Limo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor grow...

Issues in Oncology

Elizabeth Ann Mittendorf, MD, PhD, on ASCO-SITC Meeting Highlights: Expert Perspective

Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these present...

Lung Cancer

Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, ...

Solid Tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

Advertisement

Advertisement



;
Advertisement